Emerging therapeutic options for non-alcoholic fatty liver disease:A systematic review  

作　　者：Jasmine Tidwell Natalie Balassiano Anjiya Shaikh Mahmoud Nassar 

机构地区：[1]Department of Internal Medicine,University of Connecticut,Farmington,CT 06032,United States [2]Department of Internal Medicine,Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals/Queens,New York,NY 11432,United States [3]Department of Internal Medicine,Division of Endocrinology,Diabetes and Metabolism,Jacobs School of Medicine and Biomedical Sciences,University of Buffalo,Buffalo,NY 14221,United States

出　　处：《World Journal of Hepatology》2023年第8期1001-1012,共12页世界肝病学杂志（英文版）（电子版）

摘　　要：BACKGROUND Non-alcoholic fatty liver disease(NAFLD)has become a prevalent cause of chronic liver disease and ranks third among the causes of transplantation.In the United States alone,annual medical costs are approximately 100 billion dollars.Unfortunately,there is no Federal Drug Administration(FDA)-approved medication for its treatment.However,various clinical trials are investigating several therapeutic classes that could potentially treat NAFLD.It is valuable to have a compilation of the data available on their efficacy.AIM To assess the efficacy of cyclophilin inhibitors,fibroblast growth factor 21 analogs(FGF21),and dual and pan peroxisome proliferator-activated receptor(PPAR)agonists for treating NAFLD.METHODS A comprehensive literature search using keywords including cyclophilin inhibitor,FGF agonist,pan-PPAR agonists,dual-PPAR agonist,NAFLD,nonalcoholic steatohepatitis,and fatty liver was conducted on October 29,2022,in PubMed,EMBASE,Cochrane Library,Scopus and Web of Science.Animal and human research,case reports,and published articles in English from all countries with patients aged 18 and above were included.Only articles with a National Institutes of Health(NIH)Quality Assessment score of five or higher out of eight points were included.Articles that were narrative or systematic reviews,abstracts,not in English,focused on patients under 18 years old,did not measure outcomes of interest,were inaccessible,or had a low NIH Quality Assessment score were excluded.Each article was screened by two independent researchers evaluating relevance and quality.Resources were scored based on the NIH Quality Assessment Score;then,pertinent data was extracted in a spreadsheet and descriptively analyzed.RESULTS Of the 681 records screened,29 met the necessary criteria and were included in this review.These records included 12 human studies and 17 animal studies.Specifically,there were four studies on cyclophilin inhibitors,four on FGF agonists/analogs,eleven on pan-PPAR agonists,and ten on dual-PPAR agonists.Different

关 键 词：Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Cyclophilin inhibitors Fibroblast growth factor 21 analogs Dual peroxisome proliferator-activated receptor agonists Pan peroxisome proliferator-activated receptor agonists 

分 类 号：R575.5[医药卫生—消化系统]